1921
Volume 93, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract

The standard treatment of mucosal leishmaniasis (ML) is pentavalent antimonials, agents with serious adverse effects. Alternative agents include amphotericin B deoxycholate and liposomal amphotericin B. We performed a retrospective study including 29 patients treated with liposomal amphotericin B, most of whom had comorbidities, history of previous treatment of ML, and contraindications to the use of antimonial pentavalent or amphotericin B deoxycholate. We observed a cure rate of 93.1%. Kidney failure was the most important side effect, reported in five patients (17.2%). This study showed a good efficacy and safety profile of liposomal amphotericin B in patients with ML and contraindications to the use of other agents.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.15-0033
2015-12-09
2018-12-17
Loading full text...

Full text loading...

/deliver/fulltext/14761645/93/6/1214.html?itemId=/content/journals/10.4269/ajtmh.15-0033&mimeType=html&fmt=ahah

References

  1. Goto H, Lindoso JAL, , 2010. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther 8: 419433.[Crossref] [Google Scholar]
  2. Mitropoulos P, Konidas P, Durkin-Konidas M, , 2010. New World cutaneous leishmaniasis: updated review of current and future diagnosis and treatment. J Am Acad Dermatol 63: 309322.[Crossref] [Google Scholar]
  3. Amato VS, Tuon FF, Camargo RA, Souza RM, Santos CR, Nicodemo AC, , 2011. Can we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis? Am J Trop Med Hyg 85: 818819.[Crossref] [Google Scholar]
  4. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S, , 2007. Cutaneous leishmaniasis. Lancet Infect Dis 7: 581596.[Crossref] [Google Scholar]
  5. Amato VS, Tuon FF, Bacha HA, Neto VA, Nicodemo AC, , 2008. Mucosal leishmaniasis: current scenario and prospects for treatment. Acta Trop 105: 19.[Crossref] [Google Scholar]
  6. Strazzulla A, Cocuzza S, Pinzone MR, Postorino MC, Cosentino S, Serra A, Cacopardo B, Nunnari G, , 2013. Mucosal leishmaniasis: an underestimated presentation of a neglected disease. BioMed Res Int 2013: 805108.[Crossref] [Google Scholar]
  7. Ministério da Saúde do Brasil, 2007. Manual de Vigilância da Leishmaniose Tegumentar Americana. Available at: http://bvsms.saude.gov.br/bvs/publicacoes/manual_vigilancia_leishmaniose_2ed.pdf. Accessed October 16, 2014. [Google Scholar]
  8. Guerra JA, Prestes SR, Silveira H, Coelho LI, Gama P, Moura A, Amato V, Barbosa MD, Ferreira LC, , 2011. Mucosal leishmaniasis caused by Leishmania (Viannia) braziliensis and Leishmania (Viannia) guyanensis in the Brazilian Amazon. PLoS Negl Trop Dis 5: e980.[Crossref] [Google Scholar]
  9. Amato VS, Tuon FF, Imamura R, Abegão de Camargo R, Duarte MI, Neto VA, , 2009. Mucosal leishmaniasis: description of case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in Brazil. J Eur Acad Dermatol Venereol 23: 10261034.[Crossref] [Google Scholar]
  10. Amato VS, Tuon FF, Siqueira AM, Nicodemo AC, Neto VA, , 2007. Treatment of Mucosal leishmaniasis in Latin America: systematic review. Am J Trop Med Hyg 77: 266274. [Google Scholar]
  11. Goto H, Lindoso JAL, , 2012. Cutaneous and mucocutaneous leishmaniasis. Infect Dis Clin North Am 26: 293307.[Crossref] [Google Scholar]
  12. McGwire BS, Satoskar AR, , 2014. Leishmaniasis: clinical syndromes and treatment. QJM 107: 714.[Crossref] [Google Scholar]
  13. Nonata R, Sampaio R, Marsden PD, , 1997. Mucosal leishmaniasis unresponsive to glucantime therapy successfully treated with AmBisome™. Trans R Soc Trop Med Hyg 91: 77.[Crossref] [Google Scholar]
  14. Amato VS, Tuon FF, Campos A, Bacha HA, Nicodemo AC, Amato Neto V, Shikanai-Yasuda MA, , 2007. Treatment of mucosal leishmaniasis with a lipid formulation of amphotericin B. Clin Infect Dis 44: 311312.[Crossref] [Google Scholar]
  15. World Health Organization, 2010. Control of the Leishmaniases. Available at: http://whqlibdoc.who.int/trs/WHO_TRS_949_eng.pdf. Accessed October 16, 2014. [Google Scholar]
  16. Sampaio RN, Marsden PD, , 1997. Treatment of the mucosal form of leishmaniasis without response to glucantime, with liposomal amphotericin B. Rev Soc Bras Med Trop 30: 125128.[Crossref] [Google Scholar]
  17. Andrade RV, Massone C, Lucena MN, Talhari AC, Talhari S, Guerra JA, Ferreira LC, , 2011. The use of polymerase chain reaction to confirm diagnosis in skin biopsies consistent with American tegumentary leishmaniasis at histopathology: a study of 90 cases. An Bras Dermatol 86: 892896.[Crossref] [Google Scholar]
  18. Schönian G, Nasereddin A, Dinse N, Schweynoch C, Schallig HD, Presber W, Jaffe CL, , 2003. PCR diagnosis and characterization of Leishmania in local and imported clinical samples. Diagn Microbiol Infect Dis 47: 349358.[Crossref] [Google Scholar]
  19. da Silva LA, de Sousa C dos S, da Graça GC, Porrozzi R, Cupolillo E, , 2010. Sequence analysis and PCR-RFLP profiling of the hsp70 gene as a valuable tool for identifying Leishmania species associated with human leishmaniasis in Brazil. Infect Genet Evol 10: 7783.[Crossref] [Google Scholar]
  20. Motta JO, Sampaio RN, , 2012. A pilot study comparing low-dose liposomal amphotericin B with N-methyl glucamine for the treatment of American cutaneous leishmaniasis. J Eur Acad Dermatol Venereol 26: 331335.[Crossref] [Google Scholar]
  21. Monge-Maillo B, López-Vélez R, , 2013. Therapeutic options for Old World cutaneous leishmaniasis and New World cutaneous and mucocutaneous leishmaniasis. Drugs 73: 18891920.[Crossref] [Google Scholar]
  22. Satow MM, Yamashiro-Kanashiro EH, Rocha MC, Oyafuso LK, Soler RC, Cotrim PC, Lindoso JA, , 2013. Applicability of kDNA-PCR for routine diagnosis of American tegumentary leishmaniasis in a tertiary reference hospital. Rev Inst Med Trop Sao Paulo 55: 393399.[Crossref] [Google Scholar]
  23. Franke ED, Wignall FS, Cruz ME, Rosales E, Tovar AA, Lucas CM, Llanos-Cuentas A, Berman JD, , 1990. Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. Ann Intern Med 113: 934940.[Crossref] [Google Scholar]
  24. Marsden PD, , 1986. Mucosal leishmaniasis (“espundia” Escomel, 1911). Trans R Soc Trop Med Hyg 80: 859876.[Crossref] [Google Scholar]
  25. Organización Panamericana de la Salud, 2013. Leishmaniasis en las Américas: recomendaciones para el tratamiento. Available at: http://www.paho.org/hq/index.php?option=com_docman&task=doc_view&gid=22226&Itemid. Accessed October 16, 2014. [Google Scholar]
  26. Hamill RJ, , 2013. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs 73: 919934.[Crossref] [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.15-0033
Loading
/content/journals/10.4269/ajtmh.15-0033
Loading

Data & Media loading...

  • Received : 14 Jan 2015
  • Accepted : 20 Jul 2015

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error